Attached files
| file | filename |
|---|---|
| 8-K - 8-K - ModivCare Inc | modv-20210507.htm |
ModivCare Reports
First Quarter 2021 Financial Results
Denver, CO – May 7, 2021 – ModivCare Inc., (the “Company” or “ModivCare”) (Nasdaq: MODV), a technology-enabled healthcare services company that provides a suite of integrated supportive care solutions focused on improving patient outcomes, today reported financial results for the three months ended March 31, 2021.
First Quarter 2021 Highlights:
•Revenue of $453.6 million, a 23.5% increase as compared to $367.3 million in Q1 2020
•Income from continuing operations, net of tax, of $18.9 million or $1.31 per diluted common share
•Adjusted EBITDA of $48.0 million, Adjusted Net Income of $27.5 million and Adjusted EPS of $1.92
•Net cash provided by operating activities during the quarter of $134.6 million
•Cash and cash equivalents of $299.6 million at March 31, with $500.0 million debt outstanding related to the Senior Unsecured Notes
•Matrix, on a standalone basis, achieved net income of $8.6 million and Adjusted EBITDA of $32.2 million
Daniel E. Greenleaf, President and Chief Executive Officer, said, “ModivCare’s first quarter Adjusted EBITDA of $48.0 million exceeded the prior year comparable figure, reflecting higher Adjusted EBITDA in both our NEMT and Personal Care segments. In NEMT, we benefited from lower operating costs under our six-pillar strategy, expanded membership, a full quarter contribution from National MedTrans, and lower utilization under capitated contracts. Our Personal Care segment benefited from a full quarter contribution from Simplura Health Group, which we acquired in November 2020.”
Mr. Greenleaf continued, “Looking ahead, we will continue to deploy technological and operational initiatives designed to elevate the patient experience and further our market leading position in the non-emergency medical transportation industry. Yesterday we announced the acquisition of WellRyde, a leading technology provider of Advanced Transportation Management Systems (ATMS) software enabling optimized routing, automated trip assignments and billing, and real-time network monitoring. WellRyde’s technology will seamlessly integrate into our Circulation and LCAD platforms, fast-tracking our “Go Digital” initiative and accelerating our efforts to build the largest digital non-emergency medical transportation network in the nation. We will also continue to evaluate external growth opportunities in the highly fragmented $55 billion personal care sector. Simplura’s distinguished service model and stellar technology platform provide us an excellent foundation to build upon. By addressing the social determinants of health through a suite of supportive care solutions, we aim to deepen customer relationships, dismantle barriers to care, and build substantial value for shareholders.”
Mr. Greenleaf concluded, “Finally, Matrix commenced 2021 on a very positive note, with first quarter revenue more than doubling to $124 million and adjusted EBITDA more than tripling to $32.2 million compared to the respective figures for the prior year period, reflecting continued expansion of its clinical solutions business and a rebound in on-site visits in its risk assessment business.”
First Quarter 2021 Results
For the first quarter of 2021, the Company reported revenue of $453.6 million, an increase of 23.5% from $367.3 million in the first quarter of 2020.
Operating income was $28.8 million, or 6.4% of revenue, in the first quarter of 2021, compared to operating income of $10.0 million, or 2.7% of revenue, in the first quarter of 2020. Income from continuing operations, net of tax, in the first quarter of 2021 was $18.9 million, or $1.31 per diluted common share, compared to income from continuing operations, net of tax, of $16.3 million, or $1.02 per diluted common share, in the first quarter of 2020.
Adjusted EBITDA was $48.0 million, or 10.6% of revenue, in the first quarter of 2021, compared to $17.0 million, or 4.6% of revenue, in the first quarter of 2020.
Adjusted Net Income in the first quarter of 2021 was $27.5 million, or $1.92 per diluted common share, compared to $8.6 million, or $0.66 per diluted common share, in the first quarter of 2020.
Comparable adjusted EBITDA and Adjusted Net Income for Q1 2020 was recast to show the impact of stock-based compensation, which the Company is now excluding for purposes of these calculations.
The quarter-over-quarter increase in revenue was primarily due to incremental revenue of $110.2 million and $43.8 million associated with the acquisitions of Simplura and National MedTrans, respectively. This was partially offset by lower trip volume in our NEMT business caused by the continued impact of COVID-19. This lower volume resulted in a reduction of revenue in the current quarter in line with margin limitations that govern some of our profit corridor and reconciliation payor contracts.
Adjusted EBITDA increased in the first quarter of 2021 due to cost savings and productivity initiatives associated with the Company's six-pillar growth strategy in addition to incremental margin from Simplura and National MedTrans and lower utilization and contact center activity due to COVID-19. This was partially offset by higher corporate general and administrative cost as the Company continued to make investments in its employees and technology.
Matrix - Balance Sheet and Cash Flows
For the first quarter of 2021, Matrix’s revenue was $124.0 million, an increase of 102% from $61.3 million in the first quarter of 2020. Matrix had operating income of $16.1 million for the first quarter of 2021, compared to an operating loss of $1.7 million for the first quarter of 2020.
ModivCare recorded income of $4.5 million related to its Matrix equity investment compared to a loss of $2.6 million for the first quarter of 2020. For the first quarter of 2021, Matrix recorded Adjusted EBITDA of $32.2 million, or 26% of revenue, compared to $9.9 million, or 16% of revenue, for the first quarter of 2020.
Matrix’s Adjusted EBITDA for the quarter was positively impacted by its continued success with its Clinical Solutions business, which they created in the second quarter of 2020 as a response to employers’ needs for mobile health assessment resources during the pandemic. This business has continued to thrive as employers begin to transition more of their workforce back onsite. They are also beginning to experience an increase in on-site visits in their risk adjustment business to pre-pandemic levels.
As of March 31, 2021, Matrix had $262.3 million in net debt and ModivCare's ownership interest was 43.6%.
Investor Presentation and Conference Call
ModivCare will hold a conference call to discuss its financial results on Friday, May 7, 2021 at 8:00 a.m. ET. To access the call, please dial:
US toll-free: 1 (877) 423 9820
International: 1 (201) 493 6749
You may also access the conference call via webcast at investors.modivcare.com, where the call also will be archived.
About ModivCare
ModivCare Inc. ("ModivCare") (Nasdaq: MODV) is a technology-enabled healthcare services company, which provides a suite of integrated supportive care solutions for public and private payors and their patients. Our value-based solutions address the social determinants of health (SDoH), enable greater access to care, reduce costs, and improve outcomes. We are a leading provider of non-emergency medical transportation (NEMT), personal and home care, and nutritional meal delivery. ModivCare also holds a minority equity interest in CCHN Group Holdings, Inc. and its subsidiaries ("Matrix Medical Network"), which partners with leading health plans and providers nationally, delivering a broad array of assessment and care management services to individuals that improve health outcomes and health plan financial performance. For more information, please visit us at www.modivcare.com.
Non-GAAP Financial Measures and Adjustments
In addition to the financial measures prepared in accordance with generally accepted accounting principles in the United States ("GAAP"), this press release includes EBITDA and Adjusted EBITDA for the Company and its segments, as well as Adjusted Net Income and Adjusted EPS for the Company, which are performance measures that are not recognized under GAAP. EBITDA is defined as income (loss) from continuing operations, net of taxes, before: (1) interest expense, net, (2) provision (benefit) for income taxes and (3) depreciation and amortization. Adjusted EBITDA is calculated as EBITDA before certain items, including (as applicable): (1) restructuring and related charges, including severance and office closure and professional services costs related to our corporate reorganization, (2) equity in net (gain) loss of investee, (3) stock based compensation, (4) certain transaction and related costs, and (5) COVID-19 related costs, net of grant income. Adjusted Net Income is defined as income from continuing operations, net of taxes, before certain items, including (1) restructuring and related charges, (2) equity in net (gain) loss of investee, (3) stock based compensation, (4) intangible asset amortization, (5) certain transaction and related costs, (6) COVID-19 related costs, net of grant income, (7) tax impacts from the Coronavirus Aid, Relief, and Economic Security Act (the "CARES Act"), and (8) the income tax impact of such adjustments. Adjusted EPS is calculated as Adjusted Net Income less (as applicable): (1) dividends on convertible preferred stock and (2) income allocated to participating securities, divided by the diluted weighted-average number of common shares outstanding as calculated for Adjusted Net Income. Our non-GAAP performance measures exclude certain expenses and amounts that are not driven by our core operating results and may be one time in nature. Excluding these expenses makes comparisons with prior periods as well as to other companies in our industry more meaningful. We believe such measures allow investors to gain a better understanding of the factors and trends affecting the ongoing operations of our business. We consider our core operations to be the ongoing activities to provide services from which we earn revenue, including direct operating costs and indirect costs to support these activities. In addition, our net gain or loss in equity investee is excluded from these measures, as we do not have the ability to manage the venture, allocate resources within the venture, or directly control its operations or performance.
Our non-GAAP financial measures may not provide information that is directly comparable to that provided by other companies in our industry, as other companies in our industry may calculate non-GAAP financial measures differently. In addition, there are limitations in using non-GAAP financial measures because they are not prepared in accordance with GAAP, may be different from non-GAAP financial measures used by other companies, and exclude expenses that may have a material impact on our reported financial results. The presentation of non-GAAP financial measures is not intended to be considered in isolation from or as a substitute for the most directly comparable financial measures prepared in accordance with GAAP. We urge you to review the reconciliations of our non-GAAP financial measures to the most directly comparable GAAP financial measures included below, and not to rely on any single financial measure to evaluate our business.
Forward-Looking Statements
Certain statements contained in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are predictive in nature and are frequently identified by the use of terms such as “may,” “will,” “should,” “expect,” “believe,” “estimate,” “intend,” and similar words indicating possible future expectations, events or actions. Such forward-looking statements are based on current expectations, assumptions, estimates and projections about our business and our industry, and are not guarantees of our future performance. These statements are subject to a number of known and unknown risks, uncertainties and other factors, many of which are beyond our ability to control or predict, which may cause actual events to be materially different from those expressed or implied herein, including but not limited to: government or private insurance program funding reductions or limitations; alternative payment models or the transition of Medicaid and Medicare beneficiaries to Managed Care Organizations, or MCOs; our inability to control reimbursement rates received for our services; cost containment initiatives undertaken by private third-party payors; the effects of a public health emergency; inadequacies in, or security breaches of, our information technology systems, including the systems intended to protect our clients’ privacy and confidential information; any changes in the funding, financial viability or our relationships with our payors; pandemic infectious diseases, including the COVID-19 pandemic; disruptions to our contact center operations caused by health epidemics or pandemics like COVID-19; delays in collection, or non-collection, of our accounts receivable, particularly during any business integration; an impairment of our long-lived assets; any failure to maintain or to develop further reliable, efficient and secure information technology systems; an inability to attract and retain qualified employees; any acquisition or acquisition integration efforts; our contracts not surviving until the end of their stated terms, or not being renewed or extended; our failure to compete effectively in the marketplace; our not being awarded contracts through the government’s requests for proposals process, or our awarded contracts not being profitable; any failure to satisfy our contractual obligations or to maintain existing pledged performance and payment bonds; a failure to estimate accurately the cost of performing our contracts; any misclassification of the drivers we engage as independent contractors rather than as employees; significant interruptions in our communication and data services; not successfully executing on our
strategies in the face of our competition; any inability to maintain relationships with existing patient referral sources; any failure to obtain the consent of the New York Department of Health to manage the day to day operations of our licensed in-home personal care services agency business that we acquired with our Personal Care Segment; acquired unknown liabilities in connection with the acquisition of our Personal Care Segment; changes in the case-mix of our personal care patients, or changes in payor mix or payment methodologies; our loss of existing favorable managed care contracts; our experiencing shortages in qualified employees and management; labor disputes or disruptions, in particular in New York; becoming subject to malpractice or other similar claims; and our reliance on our Matrix Investment segment's financial condition.
The Company has provided additional information about the risks facing our business in our annual report on Form 10-K and subsequent filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statement was made and are expressly qualified in their entirety by the cautionary statements set forth herein and in our filings with the Securities and Exchange Commission, which you should read in their entirety before making an investment decision with respect to our securities. We undertake no obligation to update or revise any forward- looking statements contained in this release, whether as a result of new information, future events or otherwise, except as required by applicable law.
Investor Relations Contact
Kalle Ahl, The Equity Group
(212) 836-9614
kahl@equityny.com
--financial tables to follow--
ModivCare Inc.
Page 5
| ModivCare Inc. | ||||||||||||||
| Unaudited Condensed Consolidated Statements of Operations | ||||||||||||||
| (in thousands, except share and per share data) | ||||||||||||||
| Three months ended March 31, | ||||||||||||||
| 2021 | 2020 | |||||||||||||
| Service revenue, net | $ | 453,610 | $ | 367,291 | ||||||||||
| Grant income | 2,648 | — | ||||||||||||
| Operating expenses: | ||||||||||||||
| Service expense | 360,333 | 332,661 | ||||||||||||
| General and administrative expense | 54,871 | 20,795 | ||||||||||||
| Depreciation and amortization | 12,239 | 3,790 | ||||||||||||
| Total operating expenses | 427,443 | 357,246 | ||||||||||||
| Operating income | 28,815 | 10,045 | ||||||||||||
| Other expenses (income): | ||||||||||||||
| Interest expense, net | 8,423 | 241 | ||||||||||||
| Equity in net loss (income) of investee | (4,503) | 2,550 | ||||||||||||
Income from continuing operations before income taxes | 24,895 | 7,254 | ||||||||||||
| Provision (benefit) for income taxes | 6,016 | (9,046) | ||||||||||||
| Income from continuing operations, net of tax | 18,879 | 16,300 | ||||||||||||
| Loss from discontinued operations, net of tax | (39) | (202) | ||||||||||||
| Net income | $ | 18,840 | $ | 16,098 | ||||||||||
Net income available to common stockholders | $ | 18,840 | $ | 12,998 | ||||||||||
| Basic earnings (loss) per common share: | ||||||||||||||
| Continuing operations | $ | 1.33 | $ | 1.02 | ||||||||||
| Discontinued operations | — | (0.02) | ||||||||||||
| Basic earnings per common share | $ | 1.33 | $ | 1.00 | ||||||||||
| Diluted earnings (loss) per common share: | ||||||||||||||
| Continuing operations | $ | 1.31 | $ | 1.02 | ||||||||||
| Discontinued operations | — | (0.02) | ||||||||||||
| Diluted earnings per common share | $ | 1.31 | $ | 1.00 | ||||||||||
| Weighted-average number of common shares outstanding: | ||||||||||||||
| Basic | 14,158,666 | 12,987,740 | ||||||||||||
| Diluted | 14,362,226 | 13,012,991 | ||||||||||||
--more--
ModivCare Inc.
Page 6
| ModivCare Inc. | ||||||||||||||
| Unaudited Condensed Consolidated Balance Sheets | ||||||||||||||
| (in thousands) | ||||||||||||||
| March 31, 2021 | December 31, 2020 | |||||||||||||
| Assets | ||||||||||||||
| Current assets: | ||||||||||||||
| Cash and cash equivalents | $ | 299,559 | $ | 183,281 | ||||||||||
| Accounts receivable, net | 211,340 | 197,943 | ||||||||||||
Other current assets (1) | 26,194 | 44,634 | ||||||||||||
Current assets of discontinued operations (2) | 141 | 758 | ||||||||||||
| Total current assets | 537,234 | 426,616 | ||||||||||||
| Operating lease right-of-use assets | 29,398 | 30,928 | ||||||||||||
| Property and equipment, net | 30,195 | 27,544 | ||||||||||||
| Goodwill and intangible assets, net | 781,077 | 790,579 | ||||||||||||
| Equity investment | 141,220 | 137,466 | ||||||||||||
| Other assets | 12,651 | 12,780 | ||||||||||||
| Total assets | $ | 1,531,775 | $ | 1,425,913 | ||||||||||
| Liabilities and stockholders' equity | ||||||||||||||
| Current liabilities: | ||||||||||||||
| Accounts payable | $ | 33,779 | $ | 8,464 | ||||||||||
| Accrued contract payables | 245,386 | 101,705 | ||||||||||||
| Accrued expenses and other current liabilities | 119,326 | 117,010 | ||||||||||||
| Accrued transportation costs | 70,870 | 79,674 | ||||||||||||
| Current portion of operating lease liabilities | 7,922 | 8,277 | ||||||||||||
Other current liabilities (3) | 7,273 | 7,650 | ||||||||||||
Current liabilities of discontinued operations (2) | 1,527 | 1,971 | ||||||||||||
| Total current liabilities | 486,083 | 324,751 | ||||||||||||
| Long-term debt, net of deferred financing costs | 486,705 | 485,980 | ||||||||||||
| Operating lease liabilities, less current portion | 22,214 | 23,437 | ||||||||||||
| Long-term contracts payables | — | 72,183 | ||||||||||||
Other long-term liabilities (4) | 118,020 | 107,951 | ||||||||||||
| Total liabilities | 1,113,022 | 1,014,302 | ||||||||||||
| Stockholders' equity | 418,753 | 411,611 | ||||||||||||
Total liabilities and stockholders' equity | $ | 1,531,775 | $ | 1,425,913 | ||||||||||
(1) Includes other receivables, prepaid expenses and other current assets and short-term restricted cash.
(2) Includes assets or liabilities related to WD Services' former Saudi Arabian operation.
(3) Includes deferred revenue and self-funded insurance programs.
(4) Includes other long-term liabilities and deferred tax liabilities.
--more--
ModivCare Inc.
Page 7
| ModivCare Inc. | ||||||||||||||
| Unaudited Condensed Consolidated Statements of Cash Flows | ||||||||||||||
| (in thousands) | ||||||||||||||
| Three months ended March 31, | ||||||||||||||
| 2021 | 2020 | |||||||||||||
| Operating activities | ||||||||||||||
| Net income | $ | 18,840 | $ | 16,098 | ||||||||||
| Depreciation and amortization | 12,239 | 3,790 | ||||||||||||
| Stock-based compensation | 1,187 | 1,045 | ||||||||||||
| Equity in net loss (income) of investee | (4,503) | 2,550 | ||||||||||||
| Deferred income taxes | (616) | 11,590 | ||||||||||||
| Reduction of right-of-use assets | 2,745 | 2,248 | ||||||||||||
Other non-cash items (1) | 608 | 860 | ||||||||||||
Changes in working capital (2) | 104,064 | 618 | ||||||||||||
| Net cash provided by operating activities | 134,564 | 38,799 | ||||||||||||
| Investing activities | ||||||||||||||
| Purchase of property and equipment | (5,388) | (1,574) | ||||||||||||
| Net cash used in investing activities | (5,388) | (1,574) | ||||||||||||
| Financing activities | ||||||||||||||
| Proceeds from debt | — | 162,000 | ||||||||||||
| Preferred stock dividends | — | (1,095) | ||||||||||||
| Repurchase of common stock, for treasury | (14,450) | (7,299) | ||||||||||||
Proceeds from common stock issued pursuant to stock option exercise | 2,286 | 2,054 | ||||||||||||
| Restricted stock surrendered for employee tax payment | (721) | (37) | ||||||||||||
| Other financing activities | (40) | (77) | ||||||||||||
| Net cash provided by (used in) financing activities | (12,925) | 155,546 | ||||||||||||
| Net change in cash, cash equivalents and restricted cash | 116,251 | 192,771 | ||||||||||||
| Cash, cash equivalents and restricted cash at beginning of period | 183,356 | 61,673 | ||||||||||||
| Cash, cash equivalents and restricted cash at end of period | $ | 299,607 | $ | 254,444 | ||||||||||
(1) Includes provision for doubtful accounts and amortization of deferred financing costs and debt discount.
(2) Includes accounts receivable and other receivables, prepaid expenses and other current assets, self-funded insurance programs, accrued contract payables, accounts payable and accrued expenses, accrued transportation costs, deferred revenue and other long-term liabilities.
--more--
ModivCare Inc.
Page 8
ModivCare Inc.
Unaudited Reconciliation of Non-GAAP Financial Measures
Segment Information and Adjusted EBITDA
(in thousands)
| Three months ended March 31, 2021 | ||||||||||||||||||||||||||
| NEMT | Personal Care | Matrix Investment | Total Continuing Operations | |||||||||||||||||||||||
| Service revenue, net | $ | 343,416 | $ | 110,194 | $ | — | $ | 453,610 | ||||||||||||||||||
| Grant income | — | 2,648 | — | 2,648 | ||||||||||||||||||||||
| Operating expenses: | ||||||||||||||||||||||||||
| Service expense | 272,416 | 87,917 | — | 360,333 | ||||||||||||||||||||||
| General and administrative expense | 39,967 | 14,904 | — | 54,871 | ||||||||||||||||||||||
| Depreciation and amortization | 7,312 | 4,927 | — | 12,239 | ||||||||||||||||||||||
| Total operating expenses | 319,695 | 107,748 | — | 427,443 | ||||||||||||||||||||||
| Operating income | 23,721 | 5,094 | — | 28,815 | ||||||||||||||||||||||
| Other expenses (income): | ||||||||||||||||||||||||||
| Interest expense, net | 8,423 | — | — | 8,423 | ||||||||||||||||||||||
| Equity in net income of investee | — | — | (4,503) | (4,503) | ||||||||||||||||||||||
| Income from continuing | ||||||||||||||||||||||||||
| operations before income taxes | 15,298 | 5,094 | 4,503 | 24,895 | ||||||||||||||||||||||
| Provision for income taxes | 3,328 | 1,426 | 1,262 | 6,016 | ||||||||||||||||||||||
| Income from continuing operations, net of taxes | 11,970 | 3,668 | 3,241 | 18,879 | ||||||||||||||||||||||
| Interest expense, net | 8,423 | — | — | 8,423 | ||||||||||||||||||||||
| Provision for income taxes | 3,328 | 1,426 | 1,262 | 6,016 | ||||||||||||||||||||||
| Depreciation and amortization | 7,312 | 4,927 | — | 12,239 | ||||||||||||||||||||||
| EBITDA | 31,033 | 10,021 | 4,503 | 45,557 | ||||||||||||||||||||||
Restructuring and related charges (1) | 3,645 | — | — | 3,645 | ||||||||||||||||||||||
Transaction costs (2) | 2,633 | 1,045 | — | 3,678 | ||||||||||||||||||||||
| Stock-based compensation | 1,131 | — | — | 1,131 | ||||||||||||||||||||||
| COVID-19 related costs, net of grant income | 339 | (1,852) | — | (1,513) | ||||||||||||||||||||||
| Equity in net income of investee | — | — | (4,503) | (4,503) | ||||||||||||||||||||||
| Adjusted EBITDA | $ | 38,781 | $ | 9,214 | $ | — | $ | 47,995 | ||||||||||||||||||
(1) Restructuring and related charges include professional services costs of $3.2 million and severance and office closure costs of $0.4 million.
(2) Transaction costs include Circulation management incentive plan costs and acquisition costs related to Simplura Health Group and National MedTrans.
--more--
ModivCare Inc.
Page 9
ModivCare Inc.
Unaudited Reconciliation of Non-GAAP Financial Measures
Segment Information and Adjusted EBITDA
(in thousands)
| Three months ended March 31, 2020 | ||||||||||||||||||||
| NEMT | Matrix Investment | Total Continuing Operations | ||||||||||||||||||
| Service revenue, net | $ | 367,291 | $ | — | $ | 367,291 | ||||||||||||||
| Operating expenses: | ||||||||||||||||||||
| Service expense | 332,661 | — | 332,661 | |||||||||||||||||
| General and administrative expense | 20,795 | — | 20,795 | |||||||||||||||||
| Depreciation and amortization | 3,790 | — | 3,790 | |||||||||||||||||
| Total operating expenses | 357,246 | — | 357,246 | |||||||||||||||||
| Operating income | 10,045 | — | 10,045 | |||||||||||||||||
| Other expenses (income): | ||||||||||||||||||||
| Interest expense, net | 241 | — | 241 | |||||||||||||||||
| Equity in net loss of investee | — | 2,550 | 2,550 | |||||||||||||||||
| Income from continuing | ||||||||||||||||||||
| operations before income taxes | 9,804 | (2,550) | 7,254 | |||||||||||||||||
| Benefit for income taxes | (8,341) | (705) | (9,046) | |||||||||||||||||
| Income from continuing operations, net of taxes | 18,145 | (1,845) | 16,300 | |||||||||||||||||
| Interest expense, net | 241 | — | 241 | |||||||||||||||||
| Benefit for income taxes | (8,341) | (705) | (9,046) | |||||||||||||||||
| Depreciation and amortization | 3,790 | — | 3,790 | |||||||||||||||||
| EBITDA | 13,835 | (2,550) | 11,285 | |||||||||||||||||
Restructuring and related charges (1) | 1,322 | — | 1,322 | |||||||||||||||||
Transaction costs (2) | 855 | — | 855 | |||||||||||||||||
Stock-based compensation (3) | 1,007 | — | 1,007 | |||||||||||||||||
| COVID-19 related costs | 22 | — | 22 | |||||||||||||||||
| Equity in net loss of investee | — | 2,550 | 2,550 | |||||||||||||||||
| Adjusted EBITDA | $ | 17,041 | $ | — | $ | 17,041 | ||||||||||||||
(1) Restructuring and related charges include severance costs of $0.7 million and professional services costs of $0.6 million.
(2) Transaction costs include Circulation management incentive plan costs and other transaction-related expenses.
(3) Adjusted EBITDA for Q1 2020 was recast to show the impact of stock-based compensation, which the Company is now excluding for purposes of this calculation.
--more--
ModivCare Inc.
Page 10
ModivCare Inc.
Unaudited Summary Financial Information of Equity Investment in Matrix Medical Network (1)
(in thousands)
| Three months ended March 31, | |||||||||||
| 2021 | 2020 | ||||||||||
| Revenue | $ | 124,042 | $ | 61,304 | |||||||
| Operating expense | 99,503 | 53,049 | |||||||||
| Depreciation and amortization | 8,447 | 9,928 | |||||||||
| Operating income (loss) | 16,092 | (1,673) | |||||||||
| Interest expense, net | 4,081 | 5,730 | |||||||||
| Provision (benefit) for income taxes | 3,398 | (1,046) | |||||||||
| Net income (loss) | 8,613 | (6,357) | |||||||||
| Equity Interest | 43.6 | % | 43.6 | % | |||||||
| Net income (loss) - Equity Investment | 3,754 | (2,771) | |||||||||
| Management fee and other | 749 | 221 | |||||||||
| Equity in net income (loss) of investee | $ | 4,503 | $ | (2,550) | |||||||
Net Debt (2) | $ | 262,302 | $ | 290,742 | |||||||
(1)The results of our equity method investment are excluded from the calculation of ModivCare's Adjusted EBITDA and Adjusted Net Income.
(2)Net debt represents long-term debt including the current portion, excluding deferred financing costs, less cash.
--more--
ModivCare Inc.
Page 11
ModivCare Inc.
Unaudited Reconciliation of Non-GAAP Financial Measures
Adjusted EBITDA: Matrix Medical Network (1)
(in thousands)
| Three months ended March 31, | |||||||||||
| 2021 | 2020 | ||||||||||
| Revenue | $ | 124,042 | $ | 61,304 | |||||||
| Operating expense | 99,503 | 53,049 | |||||||||
| Depreciation and amortization | 8,447 | 9,928 | |||||||||
| Operating income (loss) | 16,092 | (1,673) | |||||||||
| Interest expense, net | 4,081 | 5,730 | |||||||||
| Provision (benefit) for income taxes | 3,398 | (1,046) | |||||||||
| Net income (loss) | 8,613 | (6,357) | |||||||||
| Depreciation and amortization | 8,447 | 9,928 | |||||||||
| Interest expense | 4,081 | 5,730 | |||||||||
| Provision (benefit) for income taxes | 3,398 | (1,046) | |||||||||
| EBITDA | 24,539 | 8,255 | |||||||||
| Management fees | 1,601 | 493 | |||||||||
| Integration costs | 87 | — | |||||||||
| Severance costs | 193 | 799 | |||||||||
| Restructuring expense | 4,247 | — | |||||||||
| Transaction costs | 1,525 | 385 | |||||||||
| Adjusted EBITDA | $ | 32,192 | $ | 9,932 | |||||||
(1) ModivCare accounts for its proportionate share of Matrix's results using the equity method. Matrix's Adjusted EBITDA is not included within ModivCare's Adjusted EBITDA in any period presented.
--more--
ModivCare Inc.
Page 12
ModivCare Inc.
Unaudited Reconciliation of Non-GAAP Financial Measures
Adjusted Net Income and Adjusted Net Income per Common Share:
(in thousands, except share and per share data)
| Three months ended March 31, | ||||||||||||||
| 2021 | 2020 | |||||||||||||
| Income from continuing operations, net of tax | $ | 18,879 | $ | 16,300 | ||||||||||
Restructuring and related charges(1) | 3,645 | 1,322 | ||||||||||||
Transaction costs(2) | 3,678 | 855 | ||||||||||||
Stock-based compensation(3) | 1,131 | 1,007 | ||||||||||||
| Equity in net (income) loss of investee | (4,503) | 2,550 | ||||||||||||
| Intangible amortization expense | 9,502 | 1,559 | ||||||||||||
| COVID-19 related costs, net of grant income | (1,513) | 22 | ||||||||||||
| Tax impact of the CARES Act | — | (11,060) | ||||||||||||
| Tax effected impact of adjustments | (3,302) | (1,664) | ||||||||||||
| Adjusted Net Income | 27,517 | 10,891 | ||||||||||||
| Dividends on convertible preferred stock | — | (1,095) | ||||||||||||
| Income allocated to participating securities | — | (1,177) | ||||||||||||
| Adjusted Net Income available to common stockholders | $ | 27,517 | $ | 8,619 | ||||||||||
| Adjusted earnings per share | $ | 1.92 | $ | 0.66 | ||||||||||
| Diluted weighted-average number of common shares outstanding | 14,362,226 | 13,012,991 | ||||||||||||
(1) Restructuring and related charges include severance, organizational consolidation costs and professional fees.
(2) Transaction costs include the MIP related to the Circulation acquisition and certain other transaction-related expenses.
(3) Adjusted net income for Q1 2020 was recast to show the impact of stock-based compensation, which the Company is now excluding for purposes of this calculation.